Scientific Articles

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

 

Prof Janet E Brown, MD FRCP; Kara-Louise Royle, MSc; Prof Walter Gregory, PhD; Christy Ralph, PhD; Prof Anthony Maraveyas, PhD; Omar Din, MD; Prof Timothy Eisen, MBBChir;
Prof Paul Nathan, FRCP; Prof Tom Powles, MD; Richard Griffiths, FRCP; Prof Robert Jones, PhD; Naveen Vasudev, PhD MBChB; Matthew Wheater, FRCP PhD; Abdel Hamid, FRCR MSc;
Tom Waddell, MD; Rhona McMenemin, MSc FRCR; Prof Poulam Patel, PhD; Prof James Larkin, FRCP PhD; Guy Faust, MD; Adam Martin, PhD; Jayne Swain, PhD; Janine Bestall, PhD;
Prof Christopher McCabe, PhD; David Meads, PhD; Prof Vicky Goh, MD FRCR; Prof Tze Min Wah, PhD; Prof Julia Brown, MSc; Prof Jenny Hewison, PhD; Prof Peter Selby, DSc;
Fiona Collinson, MD; on behalf of theSTAR Investigators

The Lancet Oncology, march 2023

Abstract link

Privacy Overview
AIOM

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Analytics

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.